PKU HealthCare (SZ:000788)2022-12-03 09:12Financial Performance - In the first three quarters of 2018, the company achieved operating revenue of 161,713.74 million CNY, with a net profit attributable to shareholders of 3,795.20 million CNY, representing a year-on-year growth of 28.82% [1] - As of September 30, 2018, total assets amounted to 209,188.12 million CNY, and net assets attributable to shareholders were 120,765.13 million CNY [2] - The net cash flow from operating activities for the same period was 1,034.72 million CNY, showing a significant increase of 111.67% compared to the previous year [2] Business Segments - The pharmaceutical industry segment generated operating revenue of 53,809.59 million CNY, reflecting a year-on-year increase of 75.52%, with net profit reaching 1,802.26 million CNY, up by 21.45% [2] - The pharmaceutical distribution business reported a main business income of 107,767.78 million CNY, a decline of 19.48% year-on-year, although the overall gross margin improved by 1.83% compared to the previous year [2] Strategic Goals - The company aims to achieve a market value of 10 billion CNY within two years and 30 billion CNY within five years, focusing on external acquisitions and internal development of the pharmaceutical industry [2][3] - The company plans to invest nearly 1 billion CNY in the next three years for consistency evaluation of approximately 20 products to maintain sales licenses and increase market share [3] Product Development - The company has signed contracts for projects in the rheumatology and cardiovascular fields, with a total transaction amount of 53 million CNY for the introduction of drugs such as Celecoxib capsules and Trimetazidine sustained-release tablets [3][4] - Ongoing efforts are being made to introduce products in diabetes, anti-infection, and cardiovascular areas, with core products actively undergoing consistency evaluation [4]